



ADVENT long-term outcomes (LTO) study

First long-term study from a randomized cohort comparing FARAPULSE™ PFA and thermal ablation


STUDY DESIGN

- ▶ Observational extension of the pivotal ADVENT trial. Assessed effectiveness of FARAPULSE PFA using the FARAWAVE™ Pulsed Field Ablation (PFA) Catheter vs thermal (RF or cryo) ablation out to 4 years.
- ▶ N=364 paroxysmal AFib patients (PFA n=183, thermal n=181). Average follow-up was 3.6 years.
- ▶ ADVENT LTO effectiveness endpoint defined as freedom from recurrence, cardioversion, or repeat ablation after the 3-month blanking period.



RESULTS

Effectiveness endpoint
FARAPULSE PFA showed greater long-term effectiveness vs thermal ablation



Greater freedom from hospital-based arrhythmia intervention*
for up to 4 years following ablation

85.6%
FARAPULSE PFA
(n=158/183)

VS

78.6%
Thermal ablation
(n=144/181)

(p = 0.08)

* Freedom from arrhythmia-related hospitalization or emergency dept. visit, cardioversion, or repeat ablation after the blanking period

FARAPULSE PFA patients more likely to stay off anti-arrhythmic drugs
Percentage of patients who used anti-arrhythmic drugs (AADs) out to 4 years*

FARAPULSE PFA
(n=21/183)

11.5%

Thermal ablation
(n=37/181)

20.4%

(p = 0.02)

* After 3-month blanking period



SIMILAR LONG-TERM SAFETY

No long-term safety concerns with FARAPULSE PFA

Patients treated with thermal ablation had a ~70% higher probability of needing a repeat ablation out to 4 years


Percentage of patients with repeat ablation out to 4 years



Over 90% of FARAPULSE PFA patients who were event free at 1 year were also event free long-term

The study compared time-to-event after 1 year between study groups for subjects who were event free at 1 year.

Long-term effectiveness of treatment for patients who were event free at 1 year



SUMMARY

- ✓ Long-term treatment success
- ✓ Fewer hospital-based arrhythmia interventions and repeat ablations
- ✓ Patients were more likely to stay off AADs



FARAPULSE PFA delivered long-term effectiveness at 4 years with no long term safety concerns.

Boston Scientific
Advancing science for life™

Reddy, V. Y., et al. (2026). Long-term outcomes of pulsed field ablation versus standard of care thermal ablation for paroxysmal atrial fibrillation: Primary results of the ADVENT-LTO study. Presented at AF Symposium 2026.

Results from clinical studies are not predicative of results in other studies. Results in other studies may vary.

CAUTION: The law restricts these devices to sale by or on the order of a physician. Indications, contraindications, warnings, and instructions for use can be found in the product labelling supplied with each device or at www.IFU-BSCI.com. Products shown for INFORMATION purposes only and may not be approved or for sale in certain countries. This material not intended for use in France.

© 2026 Boston Scientific Corporation or its affiliates. All rights reserved. All trademarks are the property of their respective owners. EP-2436308-AA